396 related articles for article (PubMed ID: 36810060)
1. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration.
Khachigian LM; Liew G; Teo KYC; Wong TY; Mitchell P
J Transl Med; 2023 Feb; 21(1):133. PubMed ID: 36810060
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
3. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
Luu KT; Seal J; Green M; Winskill C; Attar M
J Clin Pharmacol; 2022 May; 62(5):594-608. PubMed ID: 34783362
[TBL] [Abstract][Full Text] [Related]
4. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study.
Grimaldi G; Cancian G; Rizzato A; Casanova A; Perruchoud-Ader K; Clerici M; Consigli A; Menghini M
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1151-1159. PubMed ID: 38047930
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
7. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
8. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
9. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy.
Nair AA; Finn AP; Sternberg P
Drug Des Devel Ther; 2022; 16():3395-3400. PubMed ID: 36199631
[TBL] [Abstract][Full Text] [Related]
11. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration.
Quist SW; de Jong LA; van Asten F; Knoester P; Postma MJ; Freriks RD
Graefes Arch Clin Exp Ophthalmol; 2022 Apr; 260(4):1083-1095. PubMed ID: 34643793
[TBL] [Abstract][Full Text] [Related]
12. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
14. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
15. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
16. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.
ElSheikh RH; Chauhan MZ; Sallam AB
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358978
[TBL] [Abstract][Full Text] [Related]
17. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
18. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
19. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Berkowitz ST; Patel S
Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
[TBL] [Abstract][Full Text] [Related]
20. Cost-minimization Analysis of Ranibizumab versus Aflibercept in the Treatment of Neovascular Age-related Macular Degeneration in Colombia.
Sánchez-Thorin JC
Ophthalmic Epidemiol; 2020 Dec; 27(6):482-486. PubMed ID: 32715820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
